L26/P-720 Optimizing metformin use in polycystic ovary syndrome (MET-PCOS) - Study protocol for a double-blind randomized controlled trial
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1047 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von H.M. Hautamäki und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Is a metformin dose of 1500 mg daily inferior to 2250 mg in improving biochemical and clinical outcomes in polycystic ovary syndrome (PCOS). Summary answer This double-blind randomised controlled trial (RCT) aims to identify the optimal metformin dose for PCOS and assist physicians in treating individuals with PCOS. What is known already PCOS is one of the most prevalent endocrine disorders globally, affecting 11-13 % of women during reproductive age. PCOS is associated with an elevated risk of reproductive, metabolic, endocrine, and mental health challenges. The international PCOS guideline 2023 recommends lifestyle changes as first-line treatment for managing PCOS. In addition, metformin should be considered in individuals with a BMI ≥ 25 kg/m². Unfortunately, adverse gastrointestinal effects are common in metformin users and may lead to discontinuation of the treatment. The optimal metformin dose for individuals with PCOS is unclear, as there are very few studies comparing different metformin doses in PCOS. Study design, size, duration MET-PCOS is a double-blind RCT conducted at Helsinki University Hospital among individuals with PCOS. A total of 184 participants will be randomized (1:1) to receive a metformin dose of 1500 mg or 2250 mg per day. Study outcomes will be assessed at baseline and at 14 and 26 weeks using clinical measurements, laboratory tests, and questionnaires. Recruitment of participants began in November 2025, and the trial is expected to end by December 2027. Participants/materials, setting, methods We will include participants aged 18-37 years with a BMI ≥ 25 kg/m² and a diagnosis of PCOS according to the 2003 Rotterdam criteria. Exclusion criteria include use of hormonal contraceptives, inositol, medication for diabetes, hypercholesterolemia, or obesity, untreated hypothyroidism and hyperprolactinemia We will summarise outcomes by number of patients, mean, standard deviation, minimum and maximum values, and report mean differences. We will perform intention-to-treat analyses and sub-analyses stratified by age, BMI, and PCOS phenotype. Main results and the role of chance Outcomes include anthropometry, metabolic outcomes, hyperandrogenism, polycystic ovary morphology, menstrual cyclicity, mental health, and gastrointestinal adverse effects. Primary outcomes include weight, homeostatic model assessment for insulin resistance (HOMA-IR), hirsutism, total testosterone, severity of gastrointestinal adverse effects, and anti-Müllerian hormone (AMH). We will also assess quality of life and mental health, as well as weight stigma in individuals with PCOS, using questionnaires. Power analyses for the primary outcomes indicated that 184 participants will be needed to reveal significant differences with an 80% power. In the analyses, we estimated a 15 % dropout rate. Limitations, reasons for caution A high dropout rate due to adverse gastrointestinal effects could limit the power of the study. Therefore, intention-to-treat analyses will be performed. Adolescents (aged under 18 years) will be excluded from the study thus the results cannot be generalised to them. Wider implications of the findings MET-PCOS will shed light on the optimal metformin dose for these individuals. The optimal dose may vary depending on the symptoms and features of the patients. In that case, future treatment for PCOS should be more personalised according to individual features and lifestyle. Trial registration number Yes
Zitieren
APA
Hautamäki, H., Savolainen-Peltonen, H., Rönö, K., & Melin, J. (2026). L26/P-720 Optimizing metformin use in polycystic ovary syndrome (MET-PCOS) - Study protocol for a double-blind randomized controlled trial. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1047
Vancouver
Hautamäki H, Savolainen-Peltonen H, Rönö K, Melin J. L26/P-720 Optimizing metformin use in polycystic ovary syndrome (MET-PCOS) - Study protocol for a double-blind randomized controlled trial. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1047
BibTeX
@article{Hautamki2026,
author = {Hautamäki, H.M. and Savolainen-Peltonen, H. and Rönö, K. and Melin, J.},
title = {L26/P-720 Optimizing metformin use in polycystic ovary syndrome (MET-PCOS) - Study protocol for a double-blind randomized controlled trial},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1047}
}
EUVIMED